pubmed.ncbi.nlm.nih.gov

Cross-Reactive Antibody Responses to Novel H5Nx Influenza Viruses Following Homologous and Heterologous Prime-Boost Vaccination with a Prepandemic Stockpiled A(H5N1) Vaccine in Humans - PubMed

  • ️Sun Jan 01 2017

Cross-Reactive Antibody Responses to Novel H5Nx Influenza Viruses Following Homologous and Heterologous Prime-Boost Vaccination with a Prepandemic Stockpiled A(H5N1) Vaccine in Humans

Min Z Levine et al. J Infect Dis. 2017.

Abstract

Recently, novel highly pathogenic avian influenza H5Nx viruses (clade 2.3.4.4) caused outbreaks in US poultry. We evaluated the potential of a stockpiled A(H5N1) A/Anhui/1/2005 (clade 2.3.4) vaccine to elicit cross-reactive antibody responses to these emerging viruses. Sera from subjects who received 2 doses of MF59-adjuvanted A/Anhui/1/2005, or 1 dose of MF59-adjuvanted A/Anhui/1/2005 following priming with a clade 1 vaccine were characterized by microneutralization assays and modified hemagglutination inhibition (HI) assays. Only heterologous prime-boost vaccination induced modest cross-reactive HI antibody responses to H5Nx viruses. Heterologous prime-boost may provide a more effective vaccination strategy to broaden the antibody responses to emerging viruses.

Keywords: antibody responses; highly pathogenic avian influenza viruses; pre-pandemic stockpile.

Published by Oxford University Press for the Infectious Diseases Society of America 2017. This work is written by (a) US Government employee(s) and is in the public domain in the US.

PubMed Disclaimer

Figures

Figure 1.
Figure 1.

Hemagglutination inhibition (HI) and microneutralization (MN) antibody responses to H5N1 and H5N8 viruses 28 days following MF59-adjuvanted A/Anhui1 boost. Scatterplot of HI and MN antibody responses to A/Anhui1 (H5N1), and A/Gyr1088-6 (H5N8) 28 days post–A/Anhui1 boost. Error bars indicate 95% confidence interval. *P < .05. Abbreviations: HI, hemagglutination inhibition; MN, microneutralization; PB, Prime-Boost; VN, A/VN/1203.

Similar articles

Cited by

References

    1. World Health Organization. Cumulative number of confirmed human cases for avian influenza A(H5N1) reported to WHO, 2003–2015. http://www.who.int/influenza/human_animal_interface/EN_GIP_201503031cumu.... Accessed 3 March 2016.
    1. Smith GJ, Donis RO. Nomenclature updates resulting from the evolution of avian influenza A(H5) virus clades 2.1.3.2a, 2.2.1, and 2.3.4 during 2013–2014. Influenza Other Respir Viruses 2015; 9:271–6. - PMC - PubMed
    1. Nasreen S, Khan SU, Luby SP et al. . Highly pathogenic avian influenza A(H5N1) virus infection among workers at live bird markets, Bangladesh, 2009–2010. Emerg Infect Dis 2015; 21:629–37. - PMC - PubMed
    1. Godeaux O, Izurieta P, Madariaga M, Dramé M, Li P, Vaughn DW. Immunogenicity and safety of AS03A-adjuvanted H5N1 influenza vaccine prepared from bulk antigen after stockpiling for 4 years. Vaccine 2015; 33:2189–95. - PubMed
    1. Cioce V. Influenza vaccine and adjuvants stockpiles, Biomedical Advanced Research and Development Authority (BARDA). https://www.medicalcountermeasures.gov/BARDA/documents/Day1_VCioce-Influ.... Accessed 3 March 2016.

Publication types

MeSH terms

Substances